These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32706185)

  • 1. Development of a novel gripping test for the evaluation of the finger fine motor ability in MPTP-treated monkeys.
    Kobayashi S; Asakawa T; Nozaki T; Sugiyama K; Sameshima T; Kurozumi K
    J Integr Neurosci; 2020 Jun; 19(2):209-215. PubMed ID: 32706185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease.
    Martínez-Fernández R; Kibleur A; Chabardès S; Fraix V; Castrioto A; Lhommée E; Moro E; Lescoules L; Pelissier P; David O; Krack P
    Hum Brain Mapp; 2018 Dec; 39(12):5014-5027. PubMed ID: 30259598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
    Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease.
    Arai E; Arai M; Uchiyama T; Higuchi Y; Aoyagi K; Yamanaka Y; Yamamoto T; Nagano O; Shiina A; Maruoka D; Matsumura T; Nakagawa T; Katsuno T; Imazeki F; Saeki N; Kuwabara S; Yokosuka O
    Brain; 2012 May; 135(Pt 5):1478-85. PubMed ID: 22522940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson's disease.
    Li K; Haase R; Rüdiger H; Reimann M; Reichmann H; Wolz M; Ziemssen T
    Sci Rep; 2017 Aug; 7(1):7012. PubMed ID: 28765629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
    Vizcarra JA; Situ-Kcomt M; Artusi CA; Duker AP; Lopiano L; Okun MS; Espay AJ; Merola A
    J Neurol; 2019 Feb; 266(2):289-297. PubMed ID: 29909467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Atkinson-Clement C; Cavazzini É; Zénon A; Witjas T; Fluchère F; Azulay JP; Baunez C; Eusebio A
    Mov Disord; 2019 Mar; 34(3):377-385. PubMed ID: 30681186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease.
    Mueller K; Jech R; Růžička F; Holiga Š; Ballarini T; Bezdicek O; Möller HE; Vymazal J; Růžička E; Schroeter ML; Urgošík D
    Neuroimage Clin; 2018; 19():1025-1035. PubMed ID: 30035027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
    Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
    Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The food reaching test: a sensitive test of behavioral improvements by deep brain stimulation in MPTP-treated monkey.
    Asakawa T; Sugiyama K; Akamine S; Yokoyama C; Shukuri M; Mizuma H; Tsukada H; Onoe H; Namba H
    Neurosci Res; 2012 Oct; 74(2):122-8. PubMed ID: 22850123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial.
    Witt K; Granert O; Daniels C; Volkmann J; Falk D; van Eimeren T; Deuschl G
    Brain; 2013 Jul; 136(Pt 7):2109-19. PubMed ID: 23801735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of secondary unresponsiveness to dopaminergic drugs with preserved response to subthalamic nucleus stimulation in Parkinson's disease.
    Lenka A; Jhunjhunwala KR; Stezin A; Manjunath M; Srinivas D; Yadav R; Pal PK
    Neurol India; 2018; 66(Supplement):S135-S137. PubMed ID: 29503336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements.
    Wenzelburger R; Kopper F; Zhang BR; Witt K; Hamel W; Weinert D; Kuhtz-Buschbeck J; Gölge M; Illert M; Deuschl G; Krack P
    Mov Disord; 2003 Oct; 18(10):1162-9. PubMed ID: 14534921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of levodopa on upper limb mobility and gait in Parkinson's disease.
    Vokaer M; Azar NA; de Beyl DZ
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1304-7. PubMed ID: 12933941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
    Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus.
    Østergaard K; Aa Sunde N
    Mov Disord; 2006 May; 21(5):624-31. PubMed ID: 16283616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.
    Varma TR; Fox SH; Eldridge PR; Littlechild P; Byrne P; Forster A; Marshall A; Cameron H; McIver K; Fletcher N; Steiger M
    J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):170-4. PubMed ID: 12531942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.